Relapsed biliary tract cancer, and ASCO, beckon.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
Could RO7851624, newly into clinical trials, be RG6735?
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
No sooner does one gammadelta-focused biotech die than another takes its place.
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
